Improving the bioavailability of nintedanib by formulating inhalable ufasomes as a targeted therapy for non-small cell lung cancer

The safety and effectiveness of nintedanib in treating non-small cell lung cancer (NSCLC) have been evaluated in several clinical trials. However, nintedanib exhibits low oral bioavailability due to its poor solubility and first-pass metabolism. To enhance the sustainability, targeting, bioavailabil...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Salman M. Ghazwani, Sami Alhazmi, Salhah M. Ghazwani, Hussam M. Shubaily, Ahmed M. Wafi, Naifa Alenazi, Marwa Qadri, Amal Naif Alshammari, Wedad Mawkili, Jobran M. Moshi, Zenat Khired, Salama A. Salama
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Elsevier 2026-06-01
Serie:	International Journal of Pharmaceutics: X
Soggetti:	Lung cancer Lewis lung carcinoma Targeting Nintedanib Bioavailability
Accesso online:	http://www.sciencedirect.com/science/article/pii/S2590156725001677
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!